Abivax SA
ABVXNASDAQStock · Data from SEC EDGAR 13F · Held by 7 of 87 tracked investors
Abivax SA at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation15
- Growth18
- Profitability15
- Quality15
- Debt100
- Stability33
- ✓It has more cash than debt.
- ✓The analysts' average target is 88% above the price.
- !The company is loss-making: net profit is negative.
The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in EUR.
Is the stock expensive?
ExpensiveThe company has no earnings, so the P/E cannot be calculated.
- P/E
- –
- P/S
- 1,631.6×
- EV/EBITDA
- -22.3×
Is the company growing?
–Too few years to compare. Last year -6.8%.
Does it make money?
Loss-makingNet margin: 0.0%.
Is it financially healthy?
YesChart ABVX
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
7LA Lee Ainslie Maverick Capital | 0.05% |
PT Paul Tudor Jones Tudor Investment Corp | 0.03% |
KG Ken Griffin Citadel Advisors | 0.02% |
IE Israel Englander Millennium Management | 0.01% |
JY Jeff Yass Susquehanna International Group | 0.01% |
Ns Norský státní fond Norges Bank | 0.01% |
RB Ron Baron Baron Capital | 0% |
Frequently asked questions
How much is Abivax SA (ABVX) stock?
Abivax SA shares trade at $87.00, +0.58% over the last trading day. The price is delayed.
What is the market cap of Abivax SA?
The market cap of Abivax SA is about $7.6B.
Which big investors hold Abivax SA?
According to the latest 13F filings, 7 of 87 tracked investors hold Abivax SA, for example Lee Ainslie, Paul Tudor Jones, Ken Griffin.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.